3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
104
Stomach Neoplasms
19
Inflammatory Breast Neoplasms
12
Esophageal Neoplasms
11
Triple Negative Breast Neoplasms
6
Sarcoma
6
Carcinoma, Hepatocellular
5
Lymphoma, Large B-Cell, Diffuse
4
Liver Neoplasms
4
Adenocarcinoma Of Esophagus
4
Primary Breast Cancer
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Hemangiosarcoma
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Testicular Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neoplasm Metastasis
2
Malignant mesenchymal tumor
2
Lymphoma, B-Cell, Marginal Zone
2
Liposarcoma
2
Hemangiopericytoma, Malignant
2
Gallbladder Neoplasms
2
Fibrosarcoma
2
Desmoplastic Small Round Cell Tumor
2
Chondrosarcoma
2
Carcinoma, Ductal, Breast
2
Breast Neoplasms, Male
2
Interventions
Paclitaxel
5
Etoposide
4
Oxaliplatin
3
Ifosfamide
3
Granulocyte Colony-Stimulating Factor
3
Gemcitabine
3
Cyclophosphamide
3
Cisplatin
3
Carboplatin
3
ribociclib
2
fludarabine
2
etoposide phosphate
2
Stem Cell Transplantation
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Everolimus
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
tozuleristide
1
sonidegib
1
ripretinib
1
pralsetinib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
pazopanib
1
olaparib
1
interferon gamma-1b
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasms, Germ Cell and Embryonal
×
Epirubicin
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled